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Abstract
 
Interaction between inducible costimulator (ICOS) and its ligand is implicated in the induction
of cell-mediated and humoral immune responses. However, the molecular details of this inter-
action are unknown. We report here a mutagenesis analysis of residues in ICOS that are critical
for ligand binding. A three-dimensional model of the extracellular immunoglobulin-like do-
main of ICOS was used to map the residues conserved within the CD28 family. This analysis
identified a surface patch containing the characteristic “PPP” sequence and is conserved in hu-
man and mouse ICOS. Mutations in this region of human ICOS reduce or abolish ligand
binding. Our results suggest that the ligand binding site in ICOS maps to a region overlapping
yet distinct from the CD80/CD86 binding sites in CD28 and cytotoxic T lymphocyte antigen
 
(
 
CTLA)-4. Thus, the analysis suggests that differences in ligand binding specificity between
these related costimulatory molecules have evolved by utilization of overlapping regions with
different patterns of conserved and nonconserved residues. Two site-specific mutants generated
in the course of our studies bound ICOS ligand with higher avidity than wild-type ICOS. An
S76E mutant protein of ICOS blocked T cell costimulatory function of ICOS ligand and in-
hibited T cell response to allogeneic antigens superior to wild-type ICOS. Our studies thus
identified critical residues involving in ICOS receptor–ligand interaction and provide new
modulators for immune responses.
Key words: ICOS • CD28 • molecular model • mutagenesis • avidity
 
Introduction
 
Receptor–ligand interactions of costimulatory molecules
are required for an optimal activation of T cells stimulated
by MHC–peptide complexes expressed on APC. The inter-
actions between CD28/cytotoxic T lymphocyte antigen
(CTLA)
 
*
 
-4 on T cells with their ligands B7–1 and/or B7–2
have been intensively studied. CD28 triggering increases
antigen-specific proliferation of CD4
 
 
 
 T cells, enhances
production of cytokines, stimulates differentiation of effec-
tor function of CD8
 
 
 
 T cells (1, 2), and promotes T cell
survival (3). Signaling through CTLA-4, however, is
thought to deliver a negative signal that inhibits T cell pro-
liferation, IL-2 production, and cell cycle progression (4, 5).
Recent studies indicate that other members of the CD28
family and their B7-like ligands also participate in the regu-
lation of cellular and humoral immune response. One of
these new members is inducible costimulator (ICOS) (H4),
a CD28-like receptor and member of the Ig superfamily
(IgSF) (6, 7). Similar to CTLA-4, ICOS is induced during
T cell activation, whereas CD28 is expressed constitutively
on resting T cells. In addition to activated T cells, mature
thymocytes and thymus NK T cells also express ICOS. In
HIV-infected patients, ICOS is highly expressed in phases
characterized by high levels of viremia, and its expression
can be induced in vitro by the HIV envelope glycoprotein
gp120 (8). In independent studies, several laboratories in-
cluding ours have identified murine and human ligands of
ICOS (9–15). Engagement of ICOS by either specific anti-
bodies or its natural ligand B7-H2 (B7h, B7RP-1, GL50,
LICOS) costimulates T cell proliferation and increases pro-
duction of cytokines (6, 9). While costimulation of T cells
through ICOS induces both Th1 and Th2 cytokines, the
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effect of ICOS appears to preferentially stimulate the func-
tions of Th2 effector cells (16, 17). Blocking this interac-
tion with either ICOSIg fusion protein or specific mAb
significantly or partially inhibits dendritic cell–mediated al-
logeneic responses and antigen-specific T cell proliferation
to tetanus toxin (18), experimental allergic encephalomy-
elitis, lung mucosal inflammation, and allograft rejection
(19–21). Mice with a genetic knockout of ICOS exhibit
profound deficiencies in T cell–dependent B cell response,
impaired germinal center formation, and decreased Th2
cytokine secretion (22–24). These results implicate ICOS
and its ligand in the regulation of cell-mediated and hu-
moral immune responses.
ICOS is a type I glycoprotein with 24 and 17% amino
acid identity to CD28 and CTLA-4, respectively. Murine
and human ICOS share 69% amino acid identity. The
overall length and the relative position of the transmem-
brane segment are similar to those of CD28 and CTLA-4.
Moreover, cysteine residues that are critical for the forma-
tion of the intra- and intermolecular disulfide bonds are
conserved in ICOS and CD28/CTLA-4. ICOS contains a
single extracellular V-like Ig domain similar to CD28 and
CTLA-4 (6, 11). The V-like domains of CD28 and
CTLA-4 contain a strictly conserved MYPPPY sequence
motif that maps to the CDR3-analogous loop and is critical
for recognition of their ligands B7–1 and B7–2 (25). How-
ever, this hexapeptide motif is not conserved in ICOS.
With the aid of a three-dimensional model, we have an-
alyzed regions of ICOS that are involved in the interaction
with B7-H2. By homologue replacement and site-specific
mutagenesis, we have identified residues that are important
or essential for the interaction between ICOS and B7-H2.
Furthermore, two ICOS mutant proteins were identified
having increased avidity and improved blocking capacity
compared with wild-type ICOS.
 
Materials and Methods
 
Cell Culture.
 
Stably transfected B7-H2
 
 
 
 Chinese hamster
ovary (CHO) cells were maintained in CHO-SF II medium
(GIBCO BRL) supplemented with 10% heat-inactivated FBS
(HyClone). COS cells were grown in DMEM (GIBCO BRL)
supplemented with 10% FBS, 25 mM Hepes, 2 mM 
 
L
 
-glutamine,
1 mM sodium pyruvate, 1% MEM nonessential amino acids, and
100 U/ml penicillin G, and 100 
 
 
 
g/ml streptomycin sulfate.
 
Ig-fusion Proteins.
 
The fusion proteins with extracellular do-
main of human B7-H2 linking to either mouse IgG2a or human
IgG1 Fc portion (B7-H2mIg/B7-H2Ig) were produced in stably
transfected CHO cells and purified by protein G affinity column
as described previously (9). ICOSIg was prepared by transiently
transfecting COS cells with plasmid cDNA created by fusing the
cDNA of the extracellular domain of human ICOS in frame to
the CH2-CH3 portion of human IgG1. The transfected COS
cells were cultured in serum-free DMEM media and concentrated
supernatants were used as sources for Ig fusion proteins. The Ig
proteins were also purified with protein G column as indicated.
 
Residue Mapping.
 
The solution structure of the monomeric
extracellular IgV-like domain of CTLA-4 (26) and molecular
models of human CD28 (27) and human ICOS (28) were used to
study residue conservation in human and mouse ICOS relative to
CTLA-4 and CD28. The molecular models of CD28 and ICOS
were reported previously (27, 28) and applied herein for residue
mapping. Computer graphical analysis was performed using In-
sightII (MSI). Selected residues were subjected to a two-step mu-
tagenesis analysis. In the first (homologue replacement) step, pro-
tein segments predicted to contain residues important for ligand
binding were replaced with corresponding regions of human
CD28. In the second step, selected residues in these regions were
targeted by PCR-based site–specific mutagenesis.
 
ICOSIg Mutants.
 
Homologue replacement mutant plasmids
were designed to introduce CD28 cDNA sequences into ICOSIg
while, at the same time, deleting the equivalent region from
ICOS. All mutants of ICOSIg (see Table I) were constructed by
two-step PCR where ICOSIg cDNA was used as the template.
Overlapping oligonucleotide primers were synthesized encoding
the desired mutations and two flanking 5
 
 
 
 and 3
 
  
 
primers were
designed to contain EcoRI and BglII restriction sites, respec-
tively. Appropriate regions of cDNA were initially amplified us-
ing the corresponding overlapping and flanking primers. Then,
using the flanking 5
 
 
 
 and 3
 
 
 
 primers, fragments whose sequences
overlapped were fused together and amplified. PCR products
were digested with EcoRI and BglII and ligated into EcoRI/Bgl
II–digested pHIg vectors (9). To verify that the desired mutations
but no other mutations were introduced, each mutant was se-
quenced using an ABI Prism 310 Genetic Analyzer. Plasmids
were transfected into COS cells and serum-free supernatants were
harvested and used as sources for Ig fusion proteins or purified by
protein G column.
 
ELISA.
 
To quantitate Ig fusion proteins in culture media or
purified proteins, microtiter plates were coated with 2 
 
 
 
g/ml
goat anti–human IgG (Sigma-Aldrich) overnight at 4
 
 
 
C. Wells
were blocked for 1 h with blocking buffer (10% FBS in PBS),
then washed with PBS containing 0.05% Tween 20 (PBS-
Tween). COS cell culture media supernatants were added and in-
cubated for 2 h at room temperature. Known concentrations of
ICOSIg were also added to separate wells on each plate for the
generation of the standard curve. After washing, HRP-conju-
gated goat anti–human IgG (TAGO, Inc.) diluted at 1:2,000 was
added and incubated for 1 h at room temperature. Wells were
then washed and incubated with 3,3
 
 
 
,5,5
 
 
 
 tetramethylbenzidine
substrate for 5–15 min before stopping the reaction by the addi-
tion of 0.5 M H
 
2
 
SO
 
4
 
. Absorbance was measured at wavelengths
of 405 nm on a microtiter plate reader. Concentrations of Ig fu-
sion proteins were determined by comparison with the linear
range of a standard curve of ICOSIg. Data from triplicate wells
were determined and the standard deviations from the mean were
 
 
 
10%. Experiments were repeated at least three times. The abil-
ity of ICOSIg mutants to bind B7-H2 was measured using cap-
ture ELISA assay. Recombinant B7-H2mIg fusion proteins were
coated on microtiter plates at 5 
 
 
 
g/ml overnight at 4
 
 
 
C. Wells
were blocked, washed with PBS-Tween, and COS cell culture
media or purified proteins added and incubated for 2 h at room
temperature. After washing, HRP-conjugated goat anti–human
IgG was added followed by tetramethylbenzidine substrate and
absorbance read at 405 nm.
 
Flow Cytometry.
 
B7-H2
 
 
 
 CHO cells at 10
 
5
 
 were incubated in
FACS
 
®
 
 buffer (PBS, 3% FBS, 0.02% NaN
 
3
 
) with an equal
amount of fusion proteins in COS cell culture media on ice for
45 min. B7-H2Ig fusion protein was used as negative control.
The cells were washed and further incubated with FITC-conju-
gated goat anti–human IgG (BioSource) on ice for 30 min. Fluo-
rescence was analyzed by a FACScaliber™ flow cytometry 
1035
 
Wang et al.
(Becton Dickinson) with CellQUEST™ software (Becton Dick-
inson).
 
Surface Plasmon Resonance Analysis.
 
All experiments were
performed on a BIAcore™ 3000 instrument (Biacore) at 25
 
 
 
C
using 0.1 M Hepes, pH 7.4, containing 0.15 M NaCl, 0.005%
surfactant P20 as the running buffer. B7-H2Ig fusion protein was
covalently coupled by primary amine groups to the carboxy-
methylated dextran matrix on a CM5 sensor chip (Biacore) via
random amine coupling chemistry. The dextran surface was acti-
vated with N-ethyl-N-dimethylaminopropyl carbodiimid/N-
hydroxysuccinimide, followed by injection of 20 
 
 
 
g/ml B7-
H2Ig protein diluted in 10 mM sodium acetate buffer, pH 4.5.
The protein was exposed to the activated surface until 3,800 re-
sponse units (RU) were observed. The excess active groups on
the dextran were blocked with 1 M ethanolamine. A control sen-
sor surface was prepared by activating and blocking a separate
flow cell without protein immobilization. Wild-type and mutants
of ICOSIg were diluted to 500 nM in running buffer, and were
injected across the immobilized surfaces at a flow rate of 30 
 
 
 
l per
min for 2.66 min. Analysis of the experimental data was per-
formed using the BIAevaluation software v3.2 (BIAcore).
 
T Cell Proliferation Assays.
 
PBMCs were isolated from pe-
ripheral blood of health donors by centrifugation over Ficoll-
Hypaque and allowed to adhere to plastic dishes for 2 h. Enrich-
ment of T cells was performed by passing nonadherent PBMCs of
a healthy donor through nylon wool columns (Robbins Scien-
tific, Co.) as described previously (9). For the costimulation assay,
flat-bottomed 96-well microplates were first coated with 50 
 
 
 
l of
anti-CD3 mAb (model no. 555336; BD PharMingen) at 5 ng/ml
at 4
 
 
 
C overnight. After intensive washing with PBS, the plates
were further coated with 50 
 
 
 
l of B7-H2Ig (5 
 
 
 
g/ml) at 37
 
 
 
C for
2 h and then the purified T cells (2 
 
 
 
 10
 
5
 
 cells per well) were
added with S76E mutant protein or ICOSIg at the indicated con-
centrations to the wells in triplicate. Both S76E and ICOSIg were
purified by protein G affinity column as described previously (9).
The cells were cultured for 72 h and 
 
3
 
[H]-TdR at 1.0 
 
 
 
Ci per
well was added during the last 9 h. The incorporation of 
 
3
 
[H]-
TdR was counted by MicroBeta Trilux liquid scintillation
counter (Wallac). Allogeneic mixed lymphocyte reaction (MLR)
were set up by coculturing 10
 
5
 
 
 
 
 
-irradiated adherent cells (3,000
rad 
 
137
 
Cs) with 2 
 
 
 
 10
 
5
 
 purified allogeneic T cells in the presence
of various concentrations of S76E mutant protein or ICOSIg.
Adherent cells were prepared by incubation of purified PBMCs
of health donors for 2 h in plastic dishes. These cells were cocul-
tured in 96-well round-bottom microtiter plates for 5 d. T cell
proliferation was assessed after the addition of 1 
 
 
 
Ci per well
 
3
 
[H]-TdR for the final 9 h.
 
Results
 
Two- and Three-Dimensional Sequence Analysis of ICOS.
 
An alignment of extracellular Ig-domain sequences of the
extended CD28 family is shown in Fig. 1 a. Human and
mouse ICOS share a number of conserved residues with
CD28 and/or CTLA-4. The region corresponding to the
“MYPPPY” motif in CD28 and CTLA-4, which is critical
for B7 binding and function of these proteins, is most con-
served within this family. However, in mouse and human
ICOS, only the PPP sequence is conserved, consistent with
the finding that ICOS does not bind CD80 or CD86 (11,
29). However, the alignment identifies other regions of
ICOS-specific residue conservation. FACS
 
®
 
 analysis shows
that both human and mouse ICOSIg bind B7-H2 at a high
level, although mouse ICOSIg appears to bind less well
than its human counterpart (data not shown). This suggests
that the ligand binding sites in human and mouse ICOS are
conserved and that similar residues contribute to the bind-
ing of B7-H2 ligand. To project specific residue conserva-
tion into three dimensions, we have mapped residues con-
served in the CD28 family on the solution structure of
human CTLA-4 (26) and molecular models of human
CD28 (27) and human ICOS (28) that were built previ-
ously based on the CTLA-4 structure, as shown in Fig. 1 b.
The analysis suggests that both CD28/CTLA-4–specific
and ICOS-specific residue conservation is concentrated on
the upper part of the A
 
 
 
GFCC
 
 
 
 face of the domain, proxi-
mal to the conserved MYPPPY or PPP motifs. Some resi-
due conservation is also observed on the opposite (BED)
face of the domain. However, this region is masked by
N-linked glycosylation sites in ICOS and CD28 and
should thus not be available for ligand binding. By contrast,
no glycosylation sites are found within the conserved regions
on the A
 
 
 
GFCC
 
 
 
 face of the domain. It was previously
shown that the surface batch strictly conserved in CD28
and CTLA-4 is critical for CD80 and CD86 binding (26).
However, the region of ICOS-specific residue conserva-
tion only partly overlaps with the ligand binding site in
CD28 and CTLA-4. In the ICOS model, the spatially con-
tinuous region of conserved residues is essentially formed
by four discontinuous sequence segments, 49–52, 64–68,
75–78, and 114–119 (Fig. 1 a). Thus, on the basis of resi-
due mapping, these regions in ICOS were considered
likely to play an important role in ligand binding, and a
mutagenesis analysis was performed to assess this possibility.
 
Mutagenesis Analysis of the Interaction between ICOS and
B7-H2.
 
As a first step, the discontinuous sequence seg-
ments contributing to the formation of the conserved sur-
face patch discussed above were replaced in human ICOS
with corresponding regions of human CD28 according to
Fig. 1 a. Regions 64–68 and 75–78 encompassing the C
 
 
 
-
C
 
   
 
region were combined so that a total of three segment
swap mutants were generated (RP49–52, RP64–78, and
RP114–119). These homologue replacement constructs
were expressed as Ig fusion proteins. The concentrations of
mutant Ig fusion proteins in serum-free COS cell culture
media were determined by sandwich ELISA using anti–
human Ig mAbs. All three hybrid mutant proteins were ex-
pressed and bound by antiserum for ICOS at levels compa-
rable to wild-type ICOS. The ability of each ICOSIg
mutant to bind to B7-H2 was determined by sandwich
ELISA using B7-H2mIg and anti–human Ig mAb (Fig. 2 a)
and by FACS
 
®
 
 analysis of the ICOSIg binding to CHO
cells transfected to express B7-H2 (data not shown). Similar
results were obtained by both methods. As summarized in
Table I, mutant RP49–52 bound to B7-H2 but consider-
ably less than wild-type ICOSIg, while the mutants RP64–
78 and RP114–119 showed a complete loss of binding.
Since all three mutants displayed either significantly re-
duced (RP49–52) or abolished binding capacity to B7-H2
(RP64–78 and RP114–119), the results provided a first in- 
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Figure 1. Analysis of residue conservation in the extended CD28 family and
mapping of mutagenesis sites. (a) Structure-oriented sequence alignment. Sequences
are shown of the extracellular Ig-domains of CD28, CTLA-4, and ICOS from dif-
ferent species. b, bovine; h, human; m, mouse; r, rat.  –strands observed in the solu-
tion structure of human CTLA-4 are labeled. Assignments of residues to the A- and
C  -strands are tentative. Residue numbers are given for human ICOS. Ig V-set
consensus residues and other hydrophobic core residues are shown in lower case.
These residues are important for maintaining structural integrity but are not available
for ligand binding. Other residues conserved in CD28, CTLA-4, and ICOS are
shown in red. Residues conserved only in CD28 or CD28 and ICOS are shown in
blue, residues conserved only CTLA-4 or CTLA-4 and ICOS are shown in yellow,
and residues conserved only in ICOS are shown in green. The most conservative
residue replacements (e.g., Y/F, R/K, E/Q) are taken into account. Residues con-
served in CD28 and CTLA-4 and critical for CD80/CD86 binding are labeled with
asterisks. Potential N-linked glycosylation sites are boxed. The positions of ICOS
residues subjected to site-specific mutagenesis are labeled with exclamation marks.
(b) Three-dimensional analysis of residue conservation. A molecular model of the
extracellular domain of human ICOS, the structure of human CTLA-4, and a model
of human CD28 are shown in equivalent orientation and with solvent-accessible sur-
face representation. Residues conserved are mapped and color-coded according to a.
N-linked glycosylation sites are also mapped and colored black. Two views are
shown that focus on the opposite  –sheet surfaces of the Ig domains (top: A GFCC 
face; bottom: BED face; related by  180 degree rotation around the vertical axis). In
this orientation, the “PPP” (ICOS) and “MYPPPY” (CD28/CTLA-4) motifs are at
the top of the domains and the COOH termini at the bottom. The boxed region in
ICOS (top left image) was selected as the likely B7-H2 binding site on the basis of
residue conservation. Some ICOS-specific residue conservation is also observed on
the BED face of the domain (bottom left). However, this region is masked by a gly-
cosylation site (black), similar to the corresponding regions in CTLA-4 and CD28.
(c) Residues important for ligand binding. ICOS and CTLA-4 are shown in the
same orientation as in b, and residues are highlighted according to their importance
for ligand binding. As identified in previous mutagenesis studies (see reference 26
and references therein), residues on the A GFCC  face in CTLA-4 critical for CD80/CD86 binding are colored magenta. All of these residues are strictly
conserved in CD28. The positions of ICOS mutants that caused either abolished, reduced, or improved ligand binding are colored in magenta, gold, and
blue, respectively. Mutated ICOS residues are numbered. 
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dication that residues in these regions were either directly
(i.e., as contact residues) or indirectly (i.e., maintaining lo-
cal structural integrity) important for binding.
In the next step, we attempted to determine whether in-
dividual residues in these segments are important for B7-H2
binding. Therefore, four site-specific mutants were gen-
erated in each of the three targeted regions. These ex-
periments are summarized in Table I. Conserved residues
were selected on the basis of model analysis. Each selected
residue mapped to a position on the surface of our molecu-
lar model (and was thus predicted to be available for ligand
binding). The majority of selected residues were mutated
to serine, which is more polar than alanine and therefore
more compatible with solvent-exposed positions. The
 
PCR-generated mutant constructs were verified by DNA
sequencing, transfected into COS cells, and tested for bind-
ing by B7-H2. In the capture ELISA, mutation of Q49S
reduced the binding to B7-H2 only slightly. However,
mutants Q50S, D64S, and K69S displayed almost complete
loss of binding. The most drastic effects were observed
with mutants F51S, K67S, F114S, D115S, P117S, and
F119S, which completely abrogated B7-H2 binding capac-
ity. By contrast, two other mutants in this region, K52S
and S76E, bound B7-H2 two- or threefold better than
wild-type ICOSIg in both ELISA and FACS
 
® 
 
analysis (Fig.
2 and Table I). Therefore, our results suggest critical roles
of several residues conserved in human and mouse ICOS
for ligand binding and, in addition, provide clues for fur-
ther genetic engineering of this receptor to improve its bi-
ological activity.
 
Binding Analysis by BIAcore.
 
The binding of wild-type
and representative mutants of ICOSIg to B7-H2 was ana-
lyzed by surface plasmon resonance using a BIAcore 3000
instrument. For comparison, B7-H2Ig protein was immo-
bilized on a sensor chip and equal concentration of ICOSIg
and mutant proteins in fluid phase was passed over the
chip. The binding response of each analyte (measured in
arbitrary RU) was calculated by subtracting the response
seen in the control surface from the response seen in
the B7-H2Ig–coated surface. Equilibrium binding curves
showed results equivalent to the ELISA. In the applied
concentration, S76E and wild-type ICOSIg have a signifi-
cant difference in the association phase while another mu-
tant, P117S, which did not measurably bind by ELISA
showed minimal binding to the chips. Binding of S76E
reached equilibrium faster than wild-type ICOS while their
dissociation rates were similar (Fig. 3 and data not shown).
In addition, as shown in Fig. 3, the saturation binding level
was higher for the mutant than wild-type, then confirming
its higher avidity.
 
Increased Blockade of T Cell Responses by ICOS Mutant
Protein S76E.
 
We also tested ICOSIg mutant S76E to de-
termine whether its improved avidity correlates with an in-
creased ability to block the function of B7-H2. For these
experiments, mutant S76E was selected because it had
higher apparent avidity than K52S. We showed previously
that immobilized B7-H2Ig costimulates T cell proliferation
and cytokine production in the presence of suboptimal
doses of anti-CD3 mAb (mimicking the TCR signal) (9)
and we now have tested the effect of S76E in this system.
As shown in Fig. 4 a, wild-type ICOSIg at 1–10 
 
 
 
g/ml
significantly blocked the costimulatory effect of immobi-
lized B7-H2Ig on purified human T cells. Inclusion of
S76E protein in the culture more strongly inhibited the co-
stimulatory effect of B7-H2Ig, and blocking by S76E was
 
 
 
10-fold more effective than by wild-type ICOSIg. Inter-
estingly, the effect of the S76E protein was observed even
at 0.1 
 
 
 
g/ml while wild-type ICOSIg at the same concen-
tration did not inhibit T cell proliferation. On the basis of
these findings, mutant S76E displays clearly improved B7-H2
blocking ability.
Figure 2. Analysis of the binding ability of mutant ICOS to B7-H2.
Binding of wild-type and mutant ICOSIg to plate-bound B7-H2Ig (mIg)
fusion protein was measured by ELISA. The concentrated supernatants
(a–d) or purified proteins (e) from the cultures of transfected COS cells by
indicated ICOS mutants were used. All determinations represent the
mean of triplicate samples and differed from the mean by  10%. Shown
is a representative of three independent experiments. 
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To further explore the blocking effects of S76E mutant
protein in more physiological conditions, we also tested the
S76E mutant protein in one-way MLR to allogeneic anti-
gens. Inclusion of wild-type ICOSIg inhibited T cell pro-
liferation in MLR by up to 25% at 10 
 
 
 
g/ml compared
with the control Ig. However, S76E blocked T cell re-
sponses up to 43% (
 
P
 
 
 
  
 
0.01) at the same concentration
(Fig. 4 b). Our results thus demonstrate that mutant S76E is
superior to wild-type ICOSIg in the inhibition of T cell
responses to allogeneic antigens.
 
Discussion
 
We have applied a three-dimensional model of the ex-
tracellular domain of ICOS to map conserved regions and
thus provide a rational basis for the selection of residues for
mutagenesis. Our subsequent mutagenesis analysis has
identified several residues conserved in mouse and human
ICOS, but not CD28 or CTLA-4, that are critical for
B7-H2 binding. On the basis of these studies, we have
generated a preliminary outline of the ligand-binding site by
mapping mutated ICOS residues according to the binding
 
Table I.
 
Ligand-binding Sites of ICOS and High Avidity Mutants with Improved Function
 
Substitutions
 
a
 
Percentage of B7-H2
 
d
 
 binding activity Mutant Nucleic acids
 
b
 
Amino acids
 
c
 
ICOSIg
 
  
 
100
RP49-52 ICOS
 
145
 
 
 
156
 
/CD28
 
145
 
 
 
156
 
ICOS
 
49
 
 
 
52
 
/CD28
 
49
 
 
 
52
 
9
RP64-78 ICOS
 
190
 
 
 
234
 
/CD28
 
199
 
 
 
243
 
ICOS
 
64
 
 
 
78
 
/CD28
 
67
 
 
 
81
 
 
 
0.1
RP114-119 ICOS340 357/CD28349 366 ICOS114 119/CD28117 122  0.1
Q49S CAG/TCG Q49/S 33
Q50S CAA/TCA Q50/S 6
F51S TTT/TCT F51/S  0.1
H52S AAA/AGC K52/S 200
D64S GAT/TCT D64/S 6
K67S AAG/AGC K67/S  0.1
K69S AAA/AGC K69/S 3
S76E TCC/GAA S76/E 300
F114S TTT/TCT F114/S  0.1
D115S GAT/TCT D115/S  0.1
P117S CCT/TCT P117/S  0.1
F119S TTT/TCT F119/S  0.1
aThe regions, nucleotides, or amino acids in front of the slash were replaced with the corresponding regions, nucleotides, or amino acids after the slash.
bNucleotides are numbered from the A of the initiation codon.
cAmino acids are numbered from the initiation methionine.
dSpecific Binding activities were determined for each of the indicated fusion proteins. The concentration of a fusion protein required to give an arbi-
trary A405 the same as that found for ICISIg was determined from the linear region of binding curves and expressed as a percentage of specific binding
activity of ICOSIg. Values represent the average of three determinations from each binding curve. Values are representative of three experiments.
Figure 3. The surface plasmon resonance analysis of binding of mutant
ICOS to B7-H2. A sensorgram overlay for binding of ICOSIg and repre-
sentative mutants to immobilized B7-H2Ig is shown. Wild-type and mu-
tants of ICOSIg (500 nM) were injected separately for 2.66 min at 30  l
per min through a sensor chip with or without B7-H2Ig immobilized.
RU were calculated by subtracting the response seen in the control from
the response seen in the B7-H2Ig-coated surface. Shown is a representa-
tive of three independent experiments.1039 Wang et al.
characteristics of their mutants (Fig. 1 c). The underlying
rationale has been that mutations of selected residues either
affect binding directly or indirectly (i.e., by inducing local
structural perturbations). On the basis of the expression and
antiserum binding profiles of our mutants, the presence of
gross structural perturbations or misfolding as a conse-
quence of specific mutations was highly unlikely (consistent
with the well-known stability and sequence tolerance of
the Ig-fold). In fact, the finding that mutation of selected
residues led to differentially reduced or improved ligand
binding suggests that regions conserved in mouse and hu-
man ICOS, and targeted in this study, are directly involved
in B7-H2 binding. Although the MYPPPY motif is not
conserved in ICOS, residues in this region (114–119) are
also a major determinant of binding, similar to CD28 and
CTLA-4. However, different from CD28 and CTLA-4,
the predicted binding site in ICOS extends more in the di-
rection of the C -C   region (Fig. 1 c). Thus, we conclude
that the ligand-binding site in ICOS is, in terms of its loca-
tion and residue composition, overlapping yet distinct from
the one in CD28 and CTLA-4. This view is consistent
with the arrangement of glycosylation sites in the CD28
family and rationalizes why CD28/CTLA-4 and ICOS
bind distinct ligands. Interactions between members of the
CD28 and B7 families involve conserved structural motifs,
Ig variable-type folds, that have in part evolved to mediate
different binding specificities, which is well illustrated by
binding characteristics of ICOS. The evolutionary relation-
ship between members of the CD28 family is clearly mani-
fested by conservation of their molecular topology, the
finding that corresponding regions of the Ig-fold are em-
ployed for ligand binding, and the presence of some resid-
ual residue conservation outside protein core positions.
These include, for example, the PPP motif in ICOS that
corresponds to the MYPPPY motif in CD28 and CTLA-4,
and that is also important for binding and function. How-
ever, although structurally similar, ICOS has departed from
CD28 and CTLA-4 by using in part different and not con-
served sets of protein surface residues for ligand binding,
thus providing a molecular rationale for the modulation of
specificity within this receptor family. It is anticipated that
similar mechanisms will determine the specificity of ligands
belonging to the expanding B7 family.
Our experiments have identified two ICOS mutant pro-
teins with improved binding to B7-H2 and this has enabled
us to compare functional characteristics of such mutant
forms with wild-type ICOS. We have found that mutant
ICOSIg with improved binding ability also more effec-
tively inhibits T cell costimulatory functions of B7-H2 in
vitro, thus providing an example for the potential of engi-
neering specific cell surface receptor–ligand interactions to
modulate and improve immunoregulatory functions. We
also generated an additional double mutant combining the
two single-site mutants with increased avidity, K52S and
S76E. It was anticipated that this protein would have fur-
ther increased avidity. However, although this ICOSIg
double mutant was readily expressed and we verified that
no other spurious mutations were present in the construct,
the protein did, surprisingly, not measurably bind to B7-H2
(data not shown). Since the single-site mutations alone
did not compromise structural integrity and mapped to dis-
tant positions on the surface of the Ig-fold, the presence of
global structural defects or direct interactions between the
mutated residues is highly unlikely. Thus, the reason for
the loss of binding remains unclear and we can only specu-
late that simultaneous introduction of both changes is not
compatible with the formation of the receptor-ligand inter-
face. However, it is clear from our study that S76E has im-
proved blocking function compared with that of wild-type
Figure 4. Increased blockage of T cell responses by ICOS S76E mutant
protein. (a) S76E has improved blocking effects on T cell costimulatory
functions of B7-H2. Human T cells were cultured for 3 d with immobi-
lized anti-CD3 mAb and B7-H2Ig fusion protein in the presence of a sol-
uble form of S76E mutant protein and ICOSIg at the indicated concen-
trations for 3 d. 3[H]-TdR was added during the last 9 h of culture. (b)
S76E more strongly inhibits T cell responses to allogeneic antigens. Hu-
man T cells purified by nylon wool were cocultured with irradiated allo-
geneic adherent cells in the presence of indicated concentrations of S76E
mutant protein and ICOSIg for 5 d. 3[H]-TdR was added during the last
9 h of culture. The results were also expressed as percentage of inhibition.
Percentage of inhibition (%)   100   (average cpm of control Ig-treated
group    cpm of sample group)/(average cpm of control Ig-treated
group). Shown are the representatives of five independent experiments.1040 Binding Sites of Inducible Costimulator
ICOSIg, representing an  10-fold increase of blocking ca-
pacity. Thus, in this case, increased avidity of an ICOS mu-
tant protein correlates with improved biological effects. In
allogeneic MLR, the effect of wild-type ICOSIg appears to
be incomplete, a phenomenon that is consistent with the
involvement of other costimulatory molecules. However,
the ICOS mutant protein tested here increased blocking to
a level of  40%. Our results support the notion that the
interaction between ICOS and its ligand represents a major
costimulatory interaction during the induction of T cell re-
sponses to allogeneic antigens.
While our results suggest the possibility that ICOS mu-
tant proteins with improved ligand binding may manipu-
late T cell responses more efficiently than wild-type in
vivo, this remains to be confirmed in a clinical setting. An
alternative approach would be to engineer the mouse ho-
mologue of human ICOS and test this possibility in mouse
models. As described previously, mouse and human ICOS
have conserved ligand binding characteristics, and this
should make it possible to develop such alternative models
and provide further clues for the generation of mutant
forms for effective manipulation of T cell responses in vivo.
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